作者: Mark E. Furth , Anthony Atala
DOI: 10.1016/B978-0-12-398358-9.00006-9
关键词: Tissue engineering 、 Commercialization 、 Waiting list 、 Risk analysis (engineering) 、 Critical gap 、 Nanotechnology 、 Business 、 Endogenous regeneration 、 Cell transplantation 、 Market penetration 、 Scaffold material
摘要: Abstract Tissue engineering combines the principles of materials and cell transplantation to develop substitute tissues and/or promote endogenous regeneration. The approach was initially conceived address critical gap between growing number patients on waiting list for organ transplantation, but it will focus increasingly prevalent conditions in which restoration functional tissue would answer a currently unmet medical need. Significant progress has been realized since its inception, date only handful complex products incorporating cells together with scaffolds have gained regulatory approval, these achieved limited market penetration. Nonetheless, recent clinical reports multiple years patient follow-up document maturation field validate development neo-tissues neo-organs, industry is rapidly becoming economically robust. combination advances both commercialization indicates that technologies reach increasing numbers come.